Published in PLoS One on May 05, 2011
Landscape of EGFR signaling network in human cancers: biology and therapeutic response in relation to receptor subcellular locations. Cancer Lett (2012) 1.73
The nuclear epidermal growth factor receptor signaling network and its role in cancer. Discov Med (2011) 1.52
Nuclear EGFR as a molecular target in cancer. Radiother Oncol (2013) 1.33
Nuclear functions and subcellular trafficking mechanisms of the epidermal growth factor receptor family. Cell Biosci (2012) 1.31
Epidermal growth factor receptor targeted nuclear delivery and high-resolution whole cell X-ray imaging of Fe3O4@TiO2 nanoparticles in cancer cells. ACS Nano (2013) 1.07
Yes and Lyn play a role in nuclear translocation of the epidermal growth factor receptor. Oncogene (2012) 1.06
Hepatic stellate cell coculture enables sorafenib resistance in Huh7 cells through HGF/c-Met/Akt and Jak2/Stat3 pathways. Biomed Res Int (2014) 0.97
Plumbagin, a plant derived natural agent inhibits the growth of pancreatic cancer cells in in vitro and in vivo via targeting EGFR, Stat3 and NF-κB signaling pathways. Int J Cancer (2012) 0.93
EGF Receptor Promotes Prostate Cancer Bone Metastasis by Downregulating miR-1 and Activating TWIST1. Cancer Res (2015) 0.91
STAT1 gene expression is enhanced by nuclear EGFR and HER2 via cooperation with STAT3. Mol Carcinog (2012) 0.90
Hydroxamic Acid and Benzoic Acid-Based STAT3 Inhibitors Suppress Human Glioma and Breast Cancer Phenotypes In Vitro and In Vivo. Cancer Res (2015) 0.90
MSM enhances GH signaling via the Jak2/STAT5b pathway in osteoblast-like cells and osteoblast differentiation through the activation of STAT5b in MSCs. PLoS One (2012) 0.88
IFN signaling: how a non-canonical model led to the development of IFN mimetics. Front Immunol (2013) 0.87
Steroid-like signalling by interferons: making sense of specific gene activation by cytokines. Biochem J (2012) 0.87
Erlotinib-cisplatin combination inhibits growth and angiogenesis through c-MYC and HIF-1α in EGFR-mutated lung cancer in vitro and in vivo. Neoplasia (2015) 0.87
A facile nanoparticle immunoassay for cancer biomarker discovery. J Nanobiotechnology (2011) 0.86
Molecular subtypes of urothelial carcinoma are defined by specific gene regulatory systems. BMC Med Genomics (2015) 0.83
IGFBP2 potentiates nuclear EGFR-STAT3 signaling. Oncogene (2015) 0.82
Nuclear epidermal growth factor receptor and p16 expression in head and neck squamous cell carcinoma. Laryngoscope (2012) 0.81
Developing a nanoparticle test for prostate cancer scoring. J Transl Med (2012) 0.81
Compartmentalization of TNF-related apoptosis-inducing ligand (TRAIL) death receptor functions: emerging role of nuclear TRAIL-R2. Cell Death Dis (2014) 0.80
EGFR and HER2 signaling in breast cancer brain metastasis. Front Biosci (Elite Ed) (2016) 0.79
Non-canonical signaling mode of the epidermal growth factor receptor family. Am J Cancer Res (2015) 0.79
EGFR targeted therapies and radiation: Optimizing efficacy by appropriate drug scheduling and patient selection. Pharmacol Ther (2015) 0.79
Nuclear localization of lymphocyte-specific protein tyrosine kinase (Lck) and its role in regulating LIM domain only 2 (Lmo2) gene. Biochem Biophys Res Commun (2011) 0.79
Prediction of oncogenic interactions and cancer-related signaling networks based on network topology. PLoS One (2013) 0.79
Proteolytic cleavage, trafficking, and functions of nuclear receptor tyrosine kinases. FEBS J (2015) 0.79
Nuclear trafficking of EGFR by Vps34 represses Arf expression to promote lung tumor cell survival. Oncogene (2015) 0.79
Access to the nucleus and functional association with c-Myc is required for the full oncogenic potential of ΔEGFR/EGFRvIII. J Biol Chem (2012) 0.78
Synthetic lethality screen identifies RPS6KA2 as modifier of epidermal growth factor receptor activity in pancreatic cancer. Neoplasia (2013) 0.78
DNA-Directed Assembly of Nanogold Dimers: A Unique Dynamic Light Scattering Sensing Probe for Transcription Factor Detection. Sci Rep (2015) 0.77
A novel nuclear Src and p300 signaling axis controls migratory and invasive behavior in pancreatic cancer. Oncotarget (2016) 0.77
Regulation of therapeutic resistance in cancers by receptor tyrosine kinases. Am J Cancer Res (2016) 0.77
A molecular case report: functional assay of tyrosine kinase inhibitors in cells from a patient's primary renal cell carcinoma. Cancer Biol Ther (2012) 0.76
Resveratrol mediates cell cycle arrest and cell death in human esophageal squamous cell carcinoma by directly targeting the EGFR signaling pathway. Oncol Lett (2016) 0.75
Signal transduction by receptors with tyrosine kinase activity. Cell (1990) 22.72
Cell signaling by receptor tyrosine kinases. Cell (2000) 18.16
STATs and gene regulation. Science (1997) 16.55
Nuclear localization of EGF receptor and its potential new role as a transcription factor. Nat Cell Biol (2001) 7.22
Constitutive Stat3 activity up-regulates VEGF expression and tumor angiogenesis. Oncogene (2002) 6.17
Selective chemical probe inhibitor of Stat3, identified through structure-based virtual screening, induces antitumor activity. Proc Natl Acad Sci U S A (2007) 4.77
Stat3 activation by Src induces specific gene regulation and is required for cell transformation. Mol Cell Biol (1998) 4.22
Immortal human pancreatic duct epithelial cell lines with near normal genotype and phenotype. Am J Pathol (2000) 4.19
Dangerous liaisons: STAT3 and NF-kappaB collaboration and crosstalk in cancer. Cytokine Growth Factor Rev (2009) 4.10
c-Src-mediated phosphorylation of the epidermal growth factor receptor on Tyr845 and Tyr1101 is associated with modulation of receptor function. J Biol Chem (1999) 3.91
STAT proteins: novel molecular targets for cancer drug discovery. Oncogene (2000) 3.75
Nuclear interaction of EGFR and STAT3 in the activation of the iNOS/NO pathway. Cancer Cell (2005) 3.67
Unphosphorylated STAT3 accumulates in response to IL-6 and activates transcription by binding to NFkappaB. Genes Dev (2007) 3.57
Epidermal growth factor receptor cooperates with signal transducer and activator of transcription 3 to induce epithelial-mesenchymal transition in cancer cells via up-regulation of TWIST gene expression. Cancer Res (2007) 3.53
Mechanism of biological synergy between cellular Src and epidermal growth factor receptor. Proc Natl Acad Sci U S A (1999) 3.43
Phosphotyrosyl peptides block Stat3-mediated DNA binding activity, gene regulation, and cell transformation. J Biol Chem (2001) 3.27
Validating Stat3 in cancer therapy. Nat Med (2005) 2.96
Targeting STAT3 in cancer: how successful are we? Expert Opin Investig Drugs (2009) 2.58
Activation and association of Stat3 with Src in v-Src-transformed cell lines. Mol Cell Biol (1996) 2.47
STAT3 nuclear import is independent of tyrosine phosphorylation and mediated by importin-alpha3. Proc Natl Acad Sci U S A (2005) 2.32
Characterization of a novel tripartite nuclear localization sequence in the EGFR family. J Biol Chem (2007) 2.30
STAT proteins as novel targets for cancer drug discovery. Expert Opin Ther Targets (2004) 2.21
Activated signal transducer and activator of transcription 3 (STAT3) supports the malignant phenotype of human pancreatic cancer. Gastroenterology (2003) 2.16
Nuclear-cytoplasmic transport of EGFR involves receptor endocytosis, importin beta1 and CRM1. J Cell Biochem (2006) 2.11
Inhibition of SRC expression and activity inhibits tumor progression and metastasis of human pancreatic adenocarcinoma cells in an orthotopic nude mouse model. Am J Pathol (2006) 2.07
Induction of p21WAF1/CIP1 and cyclin D1 expression by the Src oncoprotein in mouse fibroblasts: role of activated STAT3 signaling. Oncogene (2000) 2.06
Role of the Sec61 translocon in EGF receptor trafficking to the nucleus and gene expression. Mol Biol Cell (2007) 1.99
EGFR signaling pathway in breast cancers: from traditional signal transduction to direct nuclear translocalization. Breast Cancer Res Treat (2006) 1.92
An oxazole-based small-molecule Stat3 inhibitor modulates Stat3 stability and processing and induces antitumor cell effects. ACS Chem Biol (2007) 1.79
Identification and characterization of signal transducer and activator of transcription 3 recruitment sites within the epidermal growth factor receptor. Cancer Res (2003) 1.73
Coordinated epidermal growth factor receptor pathway gene overexpression predicts epidermal growth factor receptor inhibitor sensitivity in pancreatic cancer. Cancer Res (2008) 1.69
A one-step homogeneous immunoassay for cancer biomarker detection using gold nanoparticle probes coupled with dynamic light scattering. J Am Chem Soc (2008) 1.67
Phosphotyrosine signaling networks in epidermal growth factor receptor overexpressing squamous carcinoma cells. Mol Cell Proteomics (2005) 1.63
Activation of Stat3 in v-Src-transformed fibroblasts requires cooperation of Jak1 kinase activity. J Biol Chem (2000) 1.61
Cellular physiology of STAT3: Where's the cytoplasmic monomer? J Biol Chem (1999) 1.49
Cytoplasmic transport of Stat3 by receptor-mediated endocytosis. EMBO J (2002) 1.43
Dynamic light scattering as a powerful tool for gold nanoparticle bioconjugation and biomolecular binding studies. Anal Chem (2009) 1.40
Cytokine signaling: STATS in plasma membrane rafts. J Biol Chem (2002) 1.37
Enhanced expression of epidermal growth factor receptor correlates with alterations of chromosome 7 in human pancreatic cancer. Proc Natl Acad Sci U S A (1986) 1.33
RNA helicase A is a DNA-binding partner for EGFR-mediated transcriptional activation in the nucleus. Proc Natl Acad Sci U S A (2010) 1.20
A Rac GTPase-activating protein, MgcRacGAP, is a nuclear localizing signal-containing nuclear chaperone in the activation of STAT transcription factors. Mol Cell Biol (2009) 1.12
Enhanced sensitivity of pancreatic cancer cells to concurrent inhibition of aberrant signal transducer and activator of transcription 3 and epidermal growth factor receptor or Src. J Pharmacol Exp Ther (2010) 1.12
Autocrine-mediated ErbB-2 kinase activation of STAT3 is required for growth factor independence of pancreatic cancer cell lines. Oncogene (2003) 1.12
A cell-permeable Stat3 SH2 domain mimetic inhibits Stat3 activation and induces antitumor cell effects in vitro. J Biol Chem (2010) 1.09
Association of the chaperone glucose-regulated protein 58 (GRP58/ER-60/ERp57) with Stat3 in cytosol and plasma membrane complexes. J Interferon Cytokine Res (2002) 1.08
EGF receptor deletions define a region specifically mediating STAT transcription factor activation. Biochem Biophys Res Commun (1995) 1.04
Src activation of Stat3 is an independent requirement from NF-kappaB activation for constitutive IL-8 expression in human pancreatic adenocarcinoma cells. Angiogenesis (2006) 1.03
A one-step highly sensitive method for DNA detection using dynamic light scattering. J Am Chem Soc (2008) 0.99
Protein complexes/aggregates as potential cancer biomarkers revealed by a nanoparticle aggregation immunoassay. Colloids Surf B Biointerfaces (2010) 0.89
A washing-free and amplification-free one-step homogeneous assay for protein detection using gold nanoparticle probes and dynamic light scattering. J Immunol Methods (2009) 0.81
Constitutive Stat3 activity up-regulates VEGF expression and tumor angiogenesis. Oncogene (2002) 6.17
Selective chemical probe inhibitor of Stat3, identified through structure-based virtual screening, induces antitumor activity. Proc Natl Acad Sci U S A (2007) 4.77
Ambient air pollution exaggerates adipose inflammation and insulin resistance in a mouse model of diet-induced obesity. Circulation (2009) 4.71
Targeting Stat3 blocks both HIF-1 and VEGF expression induced by multiple oncogenic growth signaling pathways. Oncogene (2005) 3.05
Persistent activation of stat3 signaling induces survivin gene expression and confers resistance to apoptosis in human breast cancer cells. Clin Cancer Res (2006) 3.00
Mechanisms of disease: Insights into the emerging role of signal transducers and activators of transcription in cancer. Nat Clin Pract Oncol (2005) 2.96
Targeting STAT3 in cancer: how successful are we? Expert Opin Investig Drugs (2009) 2.58
Activation of Stat3 by receptor tyrosine kinases and cytokines regulates survival in human non-small cell carcinoma cells. Oncogene (2003) 2.54
STAT3 as a target for inducing apoptosis in solid and hematological tumors. Cell Res (2008) 2.46
Extinction coefficient of gold nanoparticles with different sizes and different capping ligands. Colloids Surf B Biointerfaces (2006) 2.42
Stat3 controls lysosomal-mediated cell death in vivo. Nat Cell Biol (2011) 2.28
Indirubin derivatives inhibit Stat3 signaling and induce apoptosis in human cancer cells. Proc Natl Acad Sci U S A (2005) 2.00
Air pollution exposure potentiates hypertension through reactive oxygen species-mediated activation of Rho/ROCK. Arterioscler Thromb Vasc Biol (2008) 1.97
Orally bioavailable small-molecule inhibitor of transcription factor Stat3 regresses human breast and lung cancer xenografts. Proc Natl Acad Sci U S A (2012) 1.94
An oxazole-based small-molecule Stat3 inhibitor modulates Stat3 stability and processing and induces antitumor cell effects. ACS Chem Biol (2007) 1.79
A STAT3-mediated metabolic switch is involved in tumour transformation and STAT3 addiction. Aging (Albany NY) (2010) 1.70
Resveratrol inhibits Src and Stat3 signaling and induces the apoptosis of malignant cells containing activated Stat3 protein. Mol Cancer Ther (2006) 1.69
A one-step homogeneous immunoassay for cancer biomarker detection using gold nanoparticle probes coupled with dynamic light scattering. J Am Chem Soc (2008) 1.67
Constitutively active Stat3 enhances neu-mediated migration and metastasis in mammary tumors via upregulation of Cten. Cancer Res (2010) 1.60
A novel small-molecule disrupts Stat3 SH2 domain-phosphotyrosine interactions and Stat3-dependent tumor processes. Biochem Pharmacol (2010) 1.56
Air pollution and cardiac remodeling: a role for RhoA/Rho-kinase. Am J Physiol Heart Circ Physiol (2009) 1.44
Cytoplasmic transport of Stat3 by receptor-mediated endocytosis. EMBO J (2002) 1.43
The high-mobility group A1a/signal transducer and activator of transcription-3 axis: an achilles heel for hematopoietic malignancies? Cancer Res (2008) 1.43
Ambient air particulate matter exposure and tissue factor expression in atherosclerosis. Inhal Toxicol (2008) 1.40
Dynamic light scattering as a powerful tool for gold nanoparticle bioconjugation and biomolecular binding studies. Anal Chem (2009) 1.40
Hepatitis C virus (HCV) constitutively activates STAT-3 via oxidative stress: role of STAT-3 in HCV replication. J Virol (2005) 1.39
Molecular approaches towards the inhibition of the signal transducer and activator of transcription 3 (Stat3) protein. ChemMedChem (2008) 1.38
Therapeutic modulators of STAT signalling for human diseases. Nat Rev Drug Discov (2013) 1.33
Targeting protein-protein interactions: suppression of Stat3 dimerization with rationally designed small-molecule, nonpeptidic SH2 domain binders. Chembiochem (2008) 1.21
Disruption of transcriptionally active Stat3 dimers with non-phosphorylated, salicylic acid-based small molecules: potent in vitro and tumor cell activities. Chembiochem (2009) 1.20
Selective up-regulation of claudin-1 and claudin-2 in colorectal cancer. Anticancer Res (2007) 1.20
Cell-to-cell adhesion modulates Stat3 activity in normal and breast carcinoma cells. Oncogene (2004) 1.19
Gold nanoparticle-enabled biological and chemical detection and analysis. Chem Soc Rev (2011) 1.16
Isoform selective inhibition of STAT1 or STAT3 homo-dimerization via peptidomimetic probes: structural recognition of STAT SH2 domains. Bioorg Med Chem Lett (2007) 1.15
The R(h)oads to Stat3: Stat3 activation by the Rho GTPases. Exp Cell Res (2011) 1.12
Enhanced sensitivity of pancreatic cancer cells to concurrent inhibition of aberrant signal transducer and activator of transcription 3 and epidermal growth factor receptor or Src. J Pharmacol Exp Ther (2010) 1.12
Enhanced imaging and accelerated photothermalysis of A549 human lung cancer cells by gold nanospheres. Nanomedicine (Lond) (2008) 1.10
A cell-permeable Stat3 SH2 domain mimetic inhibits Stat3 activation and induces antitumor cell effects in vitro. J Biol Chem (2010) 1.09
Small molecule STAT5-SH2 domain inhibitors exhibit potent antileukemia activity. J Med Chem (2012) 1.03
Sensitization of pancreatic cancer cells to radiation by cerium oxide nanoparticle-induced ROS production. Nanomedicine (2012) 1.01
Identification of a non-phosphorylated, cell permeable, small molecule ligand for the Stat3 SH2 domain. Bioorg Med Chem Lett (2011) 1.00
Controlled functionalization of gold nanoparticles through a solid phase synthesis approach. Chem Commun (Camb) (2004) 1.00
A one-step highly sensitive method for DNA detection using dynamic light scattering. J Am Chem Soc (2008) 0.99
Stat3 is required for full neoplastic transformation by the Simian Virus 40 large tumor antigen. Mol Biol Cell (2005) 0.99
Antagonism of the Stat3-Stat3 protein dimer with salicylic acid based small molecules. ChemMedChem (2011) 0.99
Bovine and porcine gelatin sensitivity in children sensitized to milk and meat. J Allergy Clin Immunol (2009) 0.96
A nanochannel array-based electrochemical device for quantitative label-free DNA analysis. ACS Nano (2010) 0.95
The RhoU/Wrch1 Rho GTPase gene is a common transcriptional target of both the gp130/STAT3 and Wnt-1 pathways. Biochem J (2009) 0.94
Predicting detection limits of enzyme-linked immunosorbent assay (ELISA) and bioanalytical techniques in general. Analyst (2014) 0.94
Ligand-independent phosphorylation of Y869 (Y845) links mutant EGFR signaling to stat-mediated gene expression. Exp Cell Res (2007) 0.93
Monofunctional gold nanoparticles prepared via a noncovalent-interaction-based solid-phase modification approach. Small (2006) 0.92
Design, synthesis, and in vitro characterization of novel hybrid peptidomimetic inhibitors of STAT3 protein. Bioorg Med Chem (2010) 0.90
Optical limiting of a covalently bonded gold nanoparticle/polylysine hybrid material. J Phys Chem B (2005) 0.88
A label-free nanoparticle aggregation assay for protein complex/aggregate detection and study. Anal Biochem (2010) 0.86
A "nanonecklace" synthesized from monofunctionalized gold nanoparticles. J Am Chem Soc (2005) 0.86
A facile nanoparticle immunoassay for cancer biomarker discovery. J Nanobiotechnology (2011) 0.86
Coordination complex SH2 domain proteomimetics: an alternative approach to disrupting oncogenic protein-protein interactions. Chem Commun (Camb) (2009) 0.85
Identification of Purine-Scaffold Small-Molecule Inhibitors of Stat3 Activation by QSAR Studies. ACS Med Chem Lett (2010) 0.85
A study on gold nanoparticle synthesis using oleylamine as both reducing agent and protecting ligand. J Nanosci Nanotechnol (2007) 0.85
Photothermal ablation of amyloid aggregates by gold nanoparticles. Colloids Surf B Biointerfaces (2007) 0.83
Surface modification of gold nanorods through a place exchange reaction inside an ionic exchange resin. Chem Commun (Camb) (2008) 0.83
A New Metabolite with a Unique 4-Pyranone-γ-Lactam-1,4-Thiazine Moiety from a Hawaiian-Plant Associated Fungus. Org Lett (2015) 0.83
An activatable multimodal/multifunctional nanoprobe for direct imaging of intracellular drug delivery. Biomaterials (2011) 0.83
Hepatocyte growth factor-induced proliferation of hepatic stem-like cells depends on activation of NF-kappaB. J Hepatol (2004) 0.82
A nanoparticle-dendrimer conjugate prepared from a one-step chemical coupling of monofunctional nanoparticles with a dendrimer. Chem Commun (Camb) (2006) 0.81
Poly(acrylic acid)-stabilized colloidal gold nanoparticles: synthesis and properties. Nanotechnology (2010) 0.81
A washing-free and amplification-free one-step homogeneous assay for protein detection using gold nanoparticle probes and dynamic light scattering. J Immunol Methods (2009) 0.81
THAP5 is a DNA-binding transcriptional repressor that is regulated in melanoma cells during DNA damage-induced cell death. Biochem Biophys Res Commun (2010) 0.81
Differential effects of Stat3 inhibition in sparse vs confluent normal and breast cancer cells. Cancer Lett (2005) 0.81
A rapid lateral flow immunoassay for the detection of fungal alpha-amylase at the workplace. J Environ Monit (2006) 0.80
Different interaction modes of biomolecules with citrate-capped gold nanoparticles. ACS Appl Mater Interfaces (2014) 0.80
Artificially induced protein-membrane anchorage with cholesterol-based recognition agents as a new therapeutic concept. Angew Chem Int Ed Engl (2011) 0.79
Recombinant human monoclonal igA antibody against CEA to recruit neutrophils to CEA-expressing cells. Oncol Res (2008) 0.78
Hirsutinolide Series Inhibit Stat3 Activity, Alter GCN1, MAP1B, Hsp105, G6PD, Vimentin, TrxR1, and Importin α-2 Expression, and Induce Antitumor Effects against Human Glioma. J Med Chem (2015) 0.78
Rapid one-step assays for on-site monitoring of mouse and rat urinary allergens. J Environ Monit (2011) 0.78
Nasal air sampling for measuring inhaled wheat allergen in bakeries with and without facemask use. J Occup Environ Med (2006) 0.78
Buffer-stable chitosan-polyglutamic acid hybrid nanoparticles for biomedical applications. Macromol Biosci (2013) 0.77
Interparticle electromagnetic coupling in assembled gold-necklace nanoparticles. J Am Chem Soc (2007) 0.77
Comparison study of the solution phase versus solid phase place exchange reactions in the controlled functionalization of gold nanoparticles. Langmuir (2004) 0.77
In situ electroporation of large numbers of cells using minimal volumes of material. Anal Biochem (2003) 0.77
Nanoparticle delivery of inhibitory signal transducer and activator of transcription 3 G-quartet oligonucleotides blocks tumor growth in HMGA1 transgenic model of T-cell leukemia. Leuk Lymphoma (2013) 0.77
Gold nanoparticle-enabled blood test for early stage cancer detection and risk assessment. ACS Appl Mater Interfaces (2015) 0.76
Solid phase monofunctionalization of gold nanoparticles using ionic exchange resin as polymer support. J Nanosci Nanotechnol (2007) 0.75
Membrane Binding and Pore Formation by a Cytotoxic Fragment of Amyloid β Peptide. J Phys Chem B (2017) 0.75
Polymerization of a cysteinyl peptidolipid Langmuir film. Langmuir (2006) 0.75
Kinetic study of gold nanoparticle growth in solution by Brust-Schiffrin reaction. J Nanosci Nanotechnol (2006) 0.75